in this colab.paper, we examine the response to COVID19 and explore how it can be used to inform a renewed political effort to address the growing burden of cancer. We examine the role of governments, healthcare systems, partners, and communities, and shed light on the steps. We argue that by applying the lessons learned from the prioritization of the COVID19 pandemic, Canada can make meaningful progress towards improving outcomes for cancer patients.

highlights from the ASCO 2023 annual scientific meeting

ASCO20 this year ASCO was held virtually – despite this the studies presented did not disappoint. practice changing data that will alter standards of care in metastatic colorectal cancer, breast cancer and breast cancer was presented – as well as new treatment paradigms for early stage lung cancer.

highlights from the CADTH 2019 symposium held in Edmonton. AB under the theme of Supporting Healthcare Transformation

dans ce colab.paper, nous examinons la réponse au COVID19 et explorons comment elle peut être utilisée pour éclairer un effort politique renouvelé pour lutter contre le fardeau croissant du cancer. Nous examinons le rôle des gouvernements, des systèmes de santé, des partenaires et des communautés, et mettons en lumière les étapes à suivre. Nous soutenons qu’en appliquant les leçons tirées de la priorisation de la pandémie de COVID-19, le Canada peut réaliser des progrès significatifs vers l’amélioration des résultats pour les patients atteints de cancer.

highlighting abstracts from the ASCO virtual scientific program with an emphasis on value based care- here we identofy abstracts with an important clinical and economic impact.

​

Under the theme of the Learning from every patient. Caring for every patient theme, this year's highlights from ASCO2019

car t-cell therapy is a remarkable technical advancement in scientific progress on how we treat cancer, especially in that in addresses a very unmet need in a specific population. this approach is just the cusp of how we can use the immune system to treat cancer and can be expanded to cure more patients in more indications, earlier in the treatment paradigm. but only if we are able to maximize the potential of this exciting advancement now.

highlighting the main themes from the colab.paper DYING TO BE A PRIORITY

delivering innovative cancer medicines in a modern healthcare system is a daunting challenge for canadians. the introduction of CAR T cell therapy brings with it an enormous amount of complexity for our systems. establishing canada’s viability as a healthcare innovator, as a partner in delivering exceptional patient care, and a pioneer in healthcare policy that engages with stakeholders throughout the process is at a critical standpoint and we must work together to accelerate adoption of CAR-T today and to deliver the medicines of tomorrow.

summary of the practice changing abstracts from the ASCO2019 conference learning from every patient caring for every patient

implementing an oncology biosimilars strategy that improves outcomes for patients, is evidenced informed, ensures appropriate quality and safety measures are in place, and facilitates access to innovative cancer treatments